The MCC Administration's expertise in organization and facilitation removes obstacles and barriers to research, allowing MCC members to focus on science and translation. Under the leadership of new Associate Director for Administration, Seanne Falconer, MBA, FACHE, Administration drives the human resources, communications, community engagement, and non-science infrastructural activities necessary to achieve the mission and vision of the MCC. MCC Administration also conducts rigorous evaluations of progress towards the goals and objectives of MCC's Strategic Plan and continues to refine and improve practices and processes to provide excellent, cost-effective services, including the development of multiple grant management software/database systems. Administration includes 120 employees who provide support for the basic, clinical, and population research and educational missions of the MCC, as well as for the 229 research members from 53 UMN departments in 13 colleges. MCC collaborates across the UMN to showcase the collaborative opportunities and research resources of the MCC when recruiting faculty, resulting in the hiring of 33 new members since 2013. The MCC FY17 budget was $19.5M, including $2.3M (13%) in support from the CCSG. Recent major achievements by MCC Administration include renovating 7000 ft2 of space to accommodate new research collaborations; creating a Shared Resource Network in a mutually beneficial partnership with the Mayo Clinic Cancer Center; establishing the Community Engagement and Education Program to engage and educate communities about cancer prevention, treatment, survivorship, and clinical research; launching the Research Development Office to provide proactive services to build strategic capacity; and supporting strategic initiatives to increase solid-tumor therapeutic clinical trials accruals by 13% in 4 years. The grants administration team managed and supported the submission of 534 proposals (429 new) since 2013, totaling over $18 million in direct costs. This research portfolio includes an NCI training grant; an ACS institutional research grant; multiple U01s; and complex, multicomponent grants, including 5 P01s, a U54, and several multiple-PI, multi-institution grants. The administration revamped the pilot grant process to ensure that funding is aligned with the Strategic Plan's priorities, and implemented a return-on-investment (ROI) analysis on all pilot awards. During the previous grant period, pilot grant investments produced an ROI of 648%, converting $3.8M in pilot funding into $24.8M in cancer-focused research grants. MCC Administration was integral in the creation of the Minnesota Cancer Clinical Trials Network, which was designed to improve cancer outcomes by providing greater access to cancer clinical trials. The State legislature appropriated the initiative $4M annually, in perpetuity, and MCC immediately established a detailed budget, hired dedicated staff, convened partner organizations, defined legal contracting aspects of a statewide network, and issued an RFA to award funds to clinics throughout the state.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-23
Application #
10086427
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1998-06-01
Project End
2024-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
23
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ma, Bin; Zarth, Adam T; Carlson, Erik S et al. (2018) Methyl DNA Phosphate Adduct Formation in Rats Treated Chronically with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 31:48-57
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891
Lee, Hak Rae; Leslie, Faith; Azarin, Samira M (2018) A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. J Biol Eng 12:12
Yang, Libang; Herrera, Jeremy; Gilbertsen, Adam et al. (2018) IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am J Physiol Lung Cell Mol Physiol 314:L127-L136
Regan Anderson, Tarah M; Ma, Shihong; Perez Kerkvliet, Carlos et al. (2018) Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis. Mol Cancer Res 16:1761-1772
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Santiago, Victor; Lazaryan, Aleksandr; McClune, Brian et al. (2018) Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma 59:958-966
Guo, Jingshu; Villalta, Peter W; Weight, Christopher J et al. (2018) Targeted and Untargeted Detection of DNA Adducts of Aromatic Amine Carcinogens in Human Bladder by Ultra-Performance Liquid Chromatography-High-Resolution Mass Spectrometry. Chem Res Toxicol :
Boatman, Jeffrey A; Vock, David M; Koopmeiners, Joseph S et al. (2018) Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. Biostatistics 19:103-118
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. Br J Haematol 182:887-894

Showing the most recent 10 out of 1013 publications